These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24847649)

  • 41. [Development status of DAA against hepatitis C].
    Kato N; Nakagawa R; Goto K; Muroyama R; Matsubara Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():262-8. PubMed ID: 26845942
    [No Abstract]   [Full Text] [Related]  

  • 42. Development of novel anti-HCV therapies: HCV protease, helicase, and polymerase as therapeutic targets.
    Hong Z; Standring DN; Baroudy B; Lau JY
    Acta Gastroenterol Belg; 2000; 63(2):210-2. PubMed ID: 10925468
    [No Abstract]   [Full Text] [Related]  

  • 43. Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals.
    Robinson M; Tian Y; Delaney WE; Greenstein AE
    Proc Natl Acad Sci U S A; 2011 Jun; 108(25):10290-5. PubMed ID: 21646519
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SHARED: An International Collaboration to Unravel Hepatitis C Resistance.
    Howe AYM; Ceccherini-Silberstein F; Dietz J; Popping S; Grebely J; Rodrigo C; Lennerstrand J; Douglas MW; Parczewsk M; Harrigan PR; Pawlotsky JM; Garcia F; Collaborators S
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications.
    Perales C; Quer J; Gregori J; Esteban JI; Domingo E
    Viruses; 2015 Nov; 7(11):5746-66. PubMed ID: 26561827
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of antiviral resistance across acute and chronic viral infections.
    Mason S; Devincenzo JP; Toovey S; Wu JZ; Whitley RJ
    Antiviral Res; 2018 Oct; 158():103-112. PubMed ID: 30086337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Hepatitis C treatment in consideration of the carcinogenic risk and drug-resistant mutations].
    Sakamoto M; Enomoto N
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():165-70. PubMed ID: 26845924
    [No Abstract]   [Full Text] [Related]  

  • 48. Hepatitis C Virus: Discovery to epitaph in a life-time.
    Aggarwal R
    Natl Med J India; 2017; 30(2):57-60. PubMed ID: 28816209
    [No Abstract]   [Full Text] [Related]  

  • 49. High-resolution genetic profile of viral genomes: why it matters.
    Qi H; Wu NC; Du Y; Wu TT; Sun R
    Curr Opin Virol; 2015 Oct; 14():62-70. PubMed ID: 26364133
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug Resistance in Hepatitis C Virus: Future Prospects and Strategies to Combat It.
    Almas I; Afzal S; Imtiaz H; Shaheen MA; Daud M; Saghir A; Amin I; Shahid M; Idrees M
    Crit Rev Eukaryot Gene Expr; 2020; 30(4):323-336. PubMed ID: 32894662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resistance of high fitness hepatitis C virus to lethal mutagenesis.
    Gallego I; Gregori J; Soria ME; García-Crespo C; García-Álvarez M; Gómez-González A; Valiergue R; Gómez J; Esteban JI; Quer J; Domingo E; Perales C
    Virology; 2018 Oct; 523():100-109. PubMed ID: 30107298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment for hepatitis C under hemodialysis].
    Izumi N
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():294-9. PubMed ID: 26845948
    [No Abstract]   [Full Text] [Related]  

  • 53. Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection.
    Ke R; Loverdo C; Qi H; Sun R; Lloyd-Smith JO
    PLoS Comput Biol; 2015 Jun; 11(6):e1004040. PubMed ID: 26125950
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The American Association For the Study of Liver Diseases: new perspectives in the treatment of hepatitis C.
    Zeuzem S
    Antivir Ther; 2006; 11(2):267-71. PubMed ID: 16640108
    [No Abstract]   [Full Text] [Related]  

  • 55. [Treatment choice of the antiviral agent for the hepatitis C].
    Karino Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():269-73. PubMed ID: 26845943
    [No Abstract]   [Full Text] [Related]  

  • 56. From basic molecular biology to curative antiviral therapy: the success story of Hepatitis C virology.
    Reddehase MJ
    Med Microbiol Immunol; 2019 Feb; 208(1):1-2. PubMed ID: 30328536
    [No Abstract]   [Full Text] [Related]  

  • 57. Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence.
    Ke R; Li H; Wang S; Ding W; Ribeiro RM; Giorgi EE; Bhattacharya T; Barnard RJO; Hahn BH; Shaw GM; Perelson AS
    Proc Natl Acad Sci U S A; 2018 Jul; 115(30):E7139-E7148. PubMed ID: 29987026
    [TBL] [Abstract][Full Text] [Related]  

  • 58. SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection.
    Alghamdi AS; Alqutub A; Abaalkhail F; Sanai FM; Alghamdi H; Altraif I; Alswat KA; Alghamdi MY; Babatin MA; Alfaleh FZ
    Saudi J Gastroenterol; 2015; 21(2):60-3. PubMed ID: 25843190
    [No Abstract]   [Full Text] [Related]  

  • 59. [How to treat non-responders to antiviral bitherapy for hepatitis C?].
    Guyader D
    Gastroenterol Clin Biol; 2007 Mar; 31(3):317-24. PubMed ID: 17396096
    [No Abstract]   [Full Text] [Related]  

  • 60. Causes of treatment failure for hepatitis C in the era of direct-acting antiviral therapy.
    Cabezas J; Llerena S; Puente Á; Fábrega E; Crespo J
    Rev Esp Enferm Dig; 2016 Jul; 108(7):421-30. PubMed ID: 26666379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.